Bernstein initiated coverage on Dyne Therapeutics with a new price target
$DYN
Biotechnology: Pharmaceutical Preparations
Health Care
Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2025 | Outperform → Perform | Oppenheimer | |
| 8/25/2025 | $35.00 | Outperform → Strong Buy | Raymond James |
| 6/24/2025 | $13.00 | Mkt Perform | Bernstein |
| 6/11/2025 | $37.00 | Outperform | Raymond James |
| 6/2/2025 | $34.00 | Outperform | Oppenheimer |
| 5/29/2025 | $46.00 | Outperform | Evercore ISI |
| 3/12/2025 | $50.00 | Outperform | BMO Capital Markets |
| 3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
Oppenheimer downgraded Dyne Therapeutics from Outperform to Perform
Raymond James upgraded Dyne Therapeutics from Outperform to Strong Buy and set a new price target of $35.00
Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both patients and physicians - WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen (z-basivarsen, formerly known as DYNE-101), in patients with myotonic dystrophy
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. "Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped b
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage company, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for DYNE-251 in individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to exon 51 skipping. DYNE-251 is being evaluated in the ongoing Phase 1/2 DELIVER global clinical trial. "In the DELIVER trial, we've seen unprecedented and sustained functional i
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
3 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically
WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days followin
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval - - DYNE-251 in Exon 51 DMD: Based on recent FDA feedback, pursuing U.S. Accelerated Approval with dystrophin as surrogate endpoint; data from ongoing Registrational Expansion Cohort in DELIVER trial expected late 2025 with potential to support early 2026 regulatory submission - - Investor event today, January 10th at 8:00 a.m. ET - WALTHAM, Mass., Jan. 10, 2025 (GLOBE NE
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. "Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped b
Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)